Monogenic Forms of Diabetes

Slide 1 · Monogenic Forms of Diabetes

Molecular mechanisms • classification • clinicopathologic interpretation

Single-gene mechanisms

β-cell secretion

Insulin action

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Distinguish genetic defects in insulin secretion from defects in insulin action.

Explain GCK-, transcription factor–, KATP channel–, and receptor-related mechanisms.

Recognize genotype-directed diagnostic and therapeutic implications.

Classify

Mechanism

Apply

Slide 3 · One biochemical endpoint; Different diseases

Persistent hyperglycemia is the shared phenotype of diabetes.

The underlying defect may be absent insulin, inadequate secretion, or impaired insulin response.

A molecular diagnosis can therefore refine a purely clinical label.

Hyperglycemia

Distinct mechanisms

Different implications

Slide 4 · Monogenic diabetes is not simply “young-onset diabetes”

A single-gene lesion gives rise to a recognizable pathophysiologic syndrome.

Age at presentation is a clue, not a molecular diagnosis.

Genetic forms are classified separately from classic type 1 and type 2 diabetes.

Single gene

Defined pathway

Clinical phenotype

Slide 5 · Where monogenic diabetes sits in the classification

Type 1: Usually autoimmune β-cell destruction with absolute insulin deficiency.

Type 2: Insulin resistance plus inadequate β-cell compensation.

Monogenic: Primary genetic dysfunction of β cells or insulin signaling.

Type 1

β-cell destruction

Type 2

Resistance + secretion

Monogenic

Single-gene defect

Slide 6 · The two central molecular routes

Route 1: Impaired β-cell mass, glucose sensing, insulin synthesis, or secretion.

Route 2: Impaired insulin receptor synthesis, ligand binding, or kinase signaling.

Both routes can elevate circulating glucose through different proximate defects.

Hyperglycemia

β-cell defect

Insulin-action defect

Slide 7 · Why molecular subclassification matters

Phenotypically similar cases may have different natural histories.

In GCK-MODY, chronic hyperglycemia is generally mild and stable.

Several other monogenic forms require ongoing risk assessment and genotype-specific therapy.

Phenotype

Genotype

Management

Slide 8 · Normal β-cell physiology supplies the causal map

Glucose enters the β cell independently of insulin.

Glucose metabolism changes intracellular ATP availability.

Electrical activity and Ca²⁺ influx couple glucose sensing to insulin release.

Glucose

ATP rise

Ca²⁺ influx

Insulin release

Slide 9 · Insulin and C-peptide arise from one precursor

Proinsulin undergoes proteolytic processing in secretory compartments.

Mature insulin and C-peptide are released in equimolar quantities.

C-peptide provides a measure of endogenous insulin secretion.

Proinsulin

Cleavage

Insulin + C-peptide

Slide 10 · Glucose entry is only the first step

GLUT2-mediated transport permits glucose entry into β cells model.

Intracellular metabolism transduces the extracellular glucose signal.

GCK mutations perturb the glucose-sensing threshold upstream of secretion.

Transport

Glucose metabolism

ATP response

Slide 11 · ATP-sensitive potassium channels link metabolism to voltage

A rise in intracellular ATP closes ATP-sensitive K⁺ channels.

Reduced K⁺ efflux depolarizes the β-cell membrane.

Depolarization triggers voltage-gated calcium entry.

ATP ↑

KATP channel closes

Membrane depolarizes

Ca²⁺ enters

Slide 12 · Calcium is the immediate secretion signal

A rise in intracellular Ca²⁺ stimulates insulin-granule exocytosis.

The early release phase mobilizes stored insulin.

Continued glucose stimulation recruits a later, sustained phase.

Ca²⁺ influx

Granule fusion

Insulin release

Slide 13 · A receptor-level lesion acts downstream of secretion

Insulin normally binds extracellular insulin-receptor α subunits.

The β subunits contain receptor tyrosine kinase activity.

A defective receptor can produce severe resistance despite elevated insulin.

Insulin binds

Receptor RTK activates

Target-cell response

Slide 14 · IRS–PI3K–AKT transduces insulin signaling

Receptor autophosphorylation initiates recruitment of IRS proteins.

Downstream PI3-kinase and AKT regulate important metabolic responses.

Lesions in receptor function compromise this normally anabolic response.

Insulin receptor

IRS proteins

PI3K → AKT

Metabolic effects

Slide 15 · Secretory failure and resistance predict different insulin levels

An inadequate secretory response can produce hyperglycemia with insufficient insulin output.

Severe receptor resistance may coexist with compensatory hyperinsulinemia.

Insulin and C-peptide must be interpreted relative to concurrent glycemia.

β-cell failure

Insulin inadequate

Receptor defect

Insulin often high

Slide 16 · Genetic β-cell defects form a heterogeneous family

Disorders affecting β-cell mass and/or insulin production.

Some affect metabolic glucose sensing; Others affect transcriptional regulation.

The classification also includes ion-channel and insulin-gene mechanisms.

Glucose sensing

Gene regulation

Ion channels

Insulin production

Slide 17 · Scope of the β-cell classification

MODY genes listed: HNF4A, GCK, HNF1A, PDX1, HNF1B and NEUROD1.

Additional groups: Neonatal diabetes, mitochondrial diabetes, proinsulin processing defects, and INS mutations.

These categories are not interchangeable phenotypes.

MODY

Neonatal

Mitochondrial

Insulin synthesis

Slide 18 · MODY: Historical name, genetic definition

“Maturity-onset diabetes of the young” reflects an early clinical resemblance to type 2 diabetes.

Several MODY syndromes caused by germline loss-of-function variants.

The pathogenic gene—not the historical acronym alone—determines the mechanism.

Clinical resemblance

Germline variant

Defined subtype

Slide 19 · MODY often follows dominant inheritance

Many common MODY syndromes show an autosomal-dominant family pattern.

Diabetes in successive generations is a clinical clue.

De novo variants and variable expression mean that a negative family history does not absolutely exclude it.

Generation I

Generation II

Generation III

Slide 20 · A classic family history is informative, not diagnostic

Early-onset, non-autoimmune diabetes recurring across generations raises suspicion.

A family history can also reflect polygenic type 2 diabetes.

Use the complete phenotype and genetic testing rather than pedigree alone.

Pedigree

Biochemistry

Molecular result

Slide 21 · Phenotypic clues that warrant a MODY evaluation

Diabetes in youth or early adulthood without the usual features of type 1 or type 2 diabetes.

Negative islet autoantibodies and retained endogenous insulin secretion.

Stable mild fasting hyperglycemia or diabetes across successive generations.

Atypical phenotype

Autoantibodies / C-peptide

Genetic evaluation

Slide 22 · C-peptide answers a functional question

C-peptide reflects endogenous β-cell secretion.

Persisting C-peptide after diagnosis may argue against severe insulin deficiency.

C-peptide alone does not identify a particular monogenic subtype.

Secretion present?

Consider differential

Genotype still required

Slide 23 · Genetic testing establishes the molecular subtype

Select testing from the clinical phenotype and family history.

A multigene panel can examine genetically heterogeneous MODY syndromes.

Testing strategy should also consider deletions/duplications and uncertain variants.

Clinical suspicion

Appropriate assay

Variant interpretation

Slide 24 · A sequence variant is not automatically a diagnosis

Interpret pathogenicity, zygosity, inheritance, and clinical concordance.

Variants of uncertain significance do not establish a molecular diagnosis on their own.

Genetics expertise can integrate laboratory results with phenotype and counseling.

Variant detected

Evaluate evidence

Clinical classification

Slide 25 · GCK acts as a β-cell glucose sensor

Glucokinase catalyzes a rate-limiting step in oxidative glucose metabolism.

The metabolic signal helps determine when insulin secretion increases.

Loss-of-function variants shift the glycemic threshold required for secretion.

Blood glucose

Glucokinase

β-cell ATP

Insulin response

Slide 26 · GCK-MODY changes the glucose “set point”

The β cell responds as though ambient glucose were lower than it actually is.

Insulin secretion is initiated at a higher glucose concentration.

A stable elevation of fasting glucose follows from this recalibrated threshold.

Normal threshold

GCK higher threshold

Slide 27 · The characteristic GCK phenotype is stable

Typically mild, persistent fasting hyperglycemia from early life.

Glucose levels often change relatively little over time.

Identification frequently occurs incidentally, including in pregnancy or family testing.

Early life

Mild hyperglycemia

Long-term stability

Slide 28 · GCK-MODY differs in complication risk

Typical diabetes complications do not appear to develop in these patients.

2026 ADA describes microvascular complications as rare.

This should not be generalized to HNF1A- or HNF4A-associated diabetes.

GCK phenotype

Low typical complication risk

Avoid overgeneralizing

Slide 29 · GCK-MODY treatment is often unnecessary outside pregnancy

2026 ADA: Most nonpregnant individuals with GCK-MODY do not need glucose-lowering treatment.

Management depends on correct molecular identification rather than glucose value alone.

Pregnancy requires a distinct assessment; The usual rule must not be applied uncritically.

Confirmed GCK-MODY

Nonpregnant

Usually no medication

Slide 30 · GCK-MODY is not progressive MODY in disguise

GCK primarily alters glucose sensing, producing a stable threshold shift.

HNF1A/HNF4A syndromes are typically progressive secretory disorders.

The mechanism explains why clinical trajectories diverge.

GCK

Stable set point

HNF1A / HNF4A

Progressive secretion loss

Slide 31 · HNF1A-MODY: Progressive secretory dysfunction

HNF1A is a transcription-factor gene in the Robbins MODY classification.

The clinical phenotype commonly emerges in adolescence or early adulthood.

β-cell secretory function tends to deteriorate, yielding progressive hyperglycemia.

HNF1A variant

β-cell transcription

Secretion declines

Slide 32 · HNF1A-MODY can produce disproportionate glycosuria

A lower renal threshold for urinary glucose excretion is characteristic.

Glycosuria may appear at glucose concentrations lower than expected.

This clue has diagnostic value only within the wider phenotype.

Plasma glucose

Lower renal threshold

Glycosuria

Slide 33 · HNF1A-MODY often has a marked oral glucose response

The oral glucose tolerance test may show a large rise in 2-hour plasma glucose.

Marked postchallenge hyperglycemia can precede severe fasting abnormalities.

A dynamic phenotype contrasts with the smaller increments typical of GCK-MODY.

Fasting state

Oral glucose

Large postchallenge rise

Slide 34 · HNF1A-MODY is treatment-responsive to sulfonylureas

2026 ADA identifies sensitivity to sulfonylurea therapy.

This represents a genotype-dependent therapeutic distinction.

Management still requires individual assessment and hypoglycemia awareness.

Gene diagnosis

Sulfonylurea sensitivity

Individualized care

Slide 35 · HNF4A-MODY: Related progressive β-cell disease

HNF4A is another transcription-factor gene Table 24.6.

It produces a progressive insulin secretory defect.

Clinical diabetes may emerge in adolescence or adulthood.

HNF4A variant

Transcriptional dysfunction

Progressive hyperglycemia

Slide 36 · HNF4A links a neonatal phenotype to later diabetes

Some affected infants have macrosomia and transient neonatal hypoglycemia.

Later life may be marked by impaired insulin secretion and diabetes.

The phenotype changes with developmental stage; It is not contradictory.

Neonatal period

Hyperinsulinemia possible

Later life

Diabetes

Slide 37 · HNF4A-MODY may also respond to sulfonylureas

HNF4A-associated diabetes is often sulfonylurea-sensitive.

This overlaps therapeutically with HNF1A-MODY.

Gene identification remains important because associated extraglycemic features differ.

Molecular test

Therapy selection

Clinical surveillance

Slide 38 · HNF1B-MODY extends beyond the pancreatic islet

HNF1B is listed as MODY5 Table 24.6.

The phenotype includes developmental kidney disease and diabetes.

Extrapancreatic findings can be more conspicuous than hyperglycemia.

HNF1B variant

Kidney phenotype

Diabetes phenotype

Slide 39 · Renal clues are prominent in HNF1B disease

Renal cysts, hypoplasia, or other structural abnormalities may precede diabetes.

Renal magnesium wasting and hyperuricemia may also occur.

Unexplained kidney disease with diabetes warrants HNF1B consideration.

Kidney structure

Electrolyte handling

Diabetes

Slide 40 · HNF1B has additional developmental associations

Pancreatic atrophy can contribute to impaired insulin secretion.

Genitourinary abnormalities and abnormal liver tests may coexist.

Deletions encompassing HNF1B may affect neighboring genes and alter phenotype.

Pancreas

Renal / genitourinary

Other organ findings

Slide 41 · PDX1 and NEUROD1 are additional MODY genes

Robbins Table 24.6 designates PDX1 as MODY4.

The same table designates NEUROD1 as MODY6.

These genes establish genetic diversity beyond the common GCK/HNF subtypes.

PDX1 → MODY4

NEUROD1 → MODY6

Slide 42 · MODY names should be paired with gene symbols

MODY1 corresponds to HNF4A; MODY2 to GCK; MODY3 to HNF1A.

MODY4 corresponds to PDX1; MODY5 to HNF1B; MODY6 to NEUROD1.

Use the gene designation to avoid conflating clinically different disorders.

MODY1 / 2 / 3

HNF4A / GCK / HNF1A

MODY4 / 5 / 6

PDX1 / HNF1B / NEUROD1

Slide 43 · The four major MODY phenotypes are clinically separable

GCK: Stable mild hyperglycemia with low typical complication burden.

HNF1A/HNF4A: Progressive secretory dysfunction and sulfonylurea sensitivity.

HNF1B: Renal/developmental disease in addition to diabetes.

GCK

Set point

HNF1A / HNF4A

Progressive

HNF1B

Multisystem

Slide 44 · Neonatal diabetes is a separate monogenic presentation

Diagnosis before 6 months of age warrants genetic evaluation independent of current age.

2026 ADA notes that monogenic causes account for most diabetes in this window.

Neonatal diabetes may be permanent or transient.

Onset < 6 months

Genetic testing

Transient or permanent

Slide 45 · KATP channels integrate metabolic and electrical signals

The pancreatic KATP channel contains Kir6.2 and SUR1 components.

KCNJ11 encodes Kir6.2; ABCC8 encodes SUR1.

Activating variants can impair closure of the channel and insulin release.

KCNJ11 → Kir6.2

ABCC8 → SUR1

KATP conductance

Slide 46 · How KATP activation impedes insulin release

Excess channel opening preserves K⁺ efflux despite rising metabolic ATP.

β-cell depolarization and Ca²⁺ influx are impaired.

The result is deficient stimulus–secretion coupling.

KATP stays open

Less depolarization

Less Ca²⁺ entry

Less insulin

Slide 47 · KCNJ11-related permanent neonatal diabetes

Activating KCNJ11 variants are an established cause of permanent neonatal diabetes.

Extra-pancreatic manifestations can include developmental delay or seizures.

Some affected patients respond to oral sulfonylureas rather than continued insulin.

KCNJ11

Neonatal diabetes

Possible neurologic features

Slide 48 · ABCC8-related permanent neonatal diabetes

ABCC8 encodes the SUR1 channel subunit.

Activating variants can result in neonatal insulin secretory failure.

Genotype-directed sulfonylurea treatment may be effective in suitable cases.

ABCC8

SUR1

KATP-related diabetes

Slide 49 · Sulfonylureas exploit the channel mechanism

Sulfonylureas act through the SUR1-containing KATP channel complex.

Appropriate KATP-variant disease may permit successful treatment without injected insulin.

Any transition should occur under specialist supervision, not from a slide algorithm alone.

Channel target

Closure favored

Insulin secretion restored

Slide 50 · Not all permanent neonatal diabetes is KATP-mediated

INS variants can impair insulin biosynthesis and cause permanent neonatal diabetes.

2026 ADA lists insulin treatment as the preferred strategy for INS-related neonatal diabetes.

Different genes may produce the same neonatal presentation but require different treatment.

KATP-related

Sulfonylurea possible

INS-related

Insulin generally needed

Slide 51 · Transient neonatal diabetes has other mechanisms

2026 ADA includes abnormal regulation at chromosome 6q24 among transient causes.

The disease can remit in infancy and recur later.

A molecular classification is necessary even when early hyperglycemia resolves.

Early diabetes

Remission possible

Recurrence possible

Slide 52 · Neonatal diagnosis is an age-triggered genetic problem

First question: Was diabetes diagnosed in the first six months of life?

If yes, evaluate genetically regardless of later clinical status.

The result informs counseling and whether channel-targeted therapy is possible.

Age at diagnosis

Genetic assessment

Subtype-directed care

Slide 53 · Mitochondrial diabetes is a different inheritance model

Maternally inherited diabetes and deafness (MIDD).

The implicated variants are in mitochondrial DNA rather than a nuclear MODY gene.

Associated hearing loss may guide evaluation of diabetes across maternal relatives.

Maternal lineage

Diabetes

Hearing impairment

Slide 54 · Defective proinsulin conversion is also classified separately

The β cell normally processes proinsulin into mature insulin and C-peptide.

Defects in proinsulin conversion among monogenic β-cell disorders.

This mechanism is distinct from defective glucose sensing or receptor signaling.

Proinsulin

Conversion step affected

Mature insulin output

Slide 55 · INS mutations alter insulin production directly

Robbins recognizes insulin gene mutations as monogenic causes of diabetes.

These lesions affect the hormone-producing machinery itself.

The same gene category is clinically relevant to some cases of permanent neonatal diabetes.

INS gene

Insulin production

Secretory insufficiency

Slide 56 · Insulin receptor defects cause extreme resistance

Mutations may reduce receptor synthesis, insulin binding, or receptor tyrosine kinase activity.

A severe reduction in insulin action may occur despite high circulating insulin.

This phenotype as type A insulin resistance.

Receptor amount

Binding defect

Kinase defect

Slide 57 · Type A insulin resistance: Phenotype follows mechanism

Disproportionate insulin resistance is the primary abnormality.

Hyperinsulinemia reflects compensation for inadequate target-cell signaling.

Hyperglycemia develops when compensation is insufficient.

Receptor defect

Resistance

Hyperinsulinemia

Diabetes

Slide 58 · Acanthosis nigricans is a clinical clue

Velvety cutaneous hyperpigmentation in type A insulin resistance.

Acanthosis nigricans is not genetically specific on its own.

Its significance increases in the context of unusually severe resistance.

Skin finding

Severe resistance

Consider receptor defect

Slide 59 · Additional endocrine features may accompany type A resistance

Polycystic ovaries in affected females.

Elevated androgen concentrations can coexist.

The combination reflects severe insulin action impairment but is not diagnostic by itself.

Acanthosis

Hyperandrogenism

Severe resistance

Slide 60 · Lipoatrophic diabetes belongs in the insulin-action group

Robbins Table 24.6 places lipoatrophic diabetes under genetic defects in insulin action.

This categorization differs from the primary β-cell secretion group.

The classification illustrates that monogenic diabetes extends beyond MODY.

Primary secretion defect

Insulin-action disorder

Slide 61 · A mechanistic differential can start with two questions

Is insulin secretion appropriately matched to glycemia?

Is insulin resistance disproportionate to the clinical context?

A specific genetic result refines the branch-level hypothesis.

Assess secretion

Assess insulin action

Define genotype

Slide 62 · Type 1, type 2 and monogenic disease can look alike

Type 1 commonly has islet autoantibodies and progressive absolute insulin deficiency.

Type 2 commonly involves obesity-associated resistance plus β-cell dysfunction.

Monogenic disease should be considered when age, autoantibodies, insulin output and family history do not fit.

Type 1

Autoimmune

Type 2

Multifactorial

Monogenic

Pathogenic variant

Slide 63 · Common diagnostic shortcuts can misclassify patients

Youth does not automatically establish type 1 diabetes.

Absence of obesity does not prove MODY; Obesity does not exclude it.

A negative antibody result is a clue, not a pathogenic variant.

Avoid age shortcut

Avoid BMI shortcut

Confirm molecularly

Slide 64 · Case: Stable hyperglycemia across three generations

A lean 17-year-old and two first-degree relatives have longstanding mild fasting hyperglycemia.

None has progressive insulin requirement or typical diabetes complications.

The mechanism most consistent with this pattern is a raised GCK glucose threshold.

Family pattern

Mild stable glycemia

Consider GCK-MODY

Slide 65 · Case: Progressive diabetes with unusual glycosuria

A young adult has progressive hyperglycemia with preserved C-peptide and negative islet antibodies.

Glucosuria is conspicuous at modest plasma glucose concentrations.

HNF1A-MODY is a reasonable molecular hypothesis; Confirm by genetic testing.

Progressive secretion loss

Low renal threshold

Consider HNF1A

Slide 66 · Case: Diabetes accompanied by renal cysts

A patient has early-onset diabetes plus congenital renal cystic changes.

The phenotype involves development of organs outside the islet.

HNF1B is the key gene to consider, while retaining a broader differential.

Diabetes

Renal developmental disease

Consider HNF1B

Slide 67 · Case: Diabetes diagnosed at eight weeks

An infant requires insulin treatment for marked hyperglycemia.

Diagnosis under six months mandates consideration of neonatal diabetes genetics.

KCNJ11, ABCC8 and INS are relevant genes; Test before assuming a treatment mechanism.

<6 months onset

Genetic test

Gene-specific therapy

Slide 68 · Case: Severe resistance despite high insulin

A young person has acanthosis nigricans, very high insulin, and hyperglycemia.

The primary deficit may lie at the insulin receptor rather than insulin production.

A targeted assessment for type A insulin resistance is appropriate.

High insulin

Poor insulin response

Consider INSR-related disease

Slide 69 · Why tissue microscopy is not the primary classifier

These diseases are fundamentally molecular and functional rather than defined by a characteristic routine biopsy pattern.

Glucose sensing, hormone synthesis, and receptor signaling cannot be diagnosed by nonspecific islet morphology alone.

Biochemical phenotype plus verified molecular testing is more discriminating.

Functional phenotype

Genetics

Not routine histology

Slide 70 · Clinical utility follows the causal gene

GCK: Distinguish stable threshold hyperglycemia from progressive diabetes.

HNF1A/HNF4A and selected KATP defects: Consider genotype-directed therapy.

HNF1B or MIDD: Actively recognize associated non-glycemic findings.

Diagnosis

Therapeutic response

Family / organ screening

Slide 71 · A compact mechanism-based synthesis

β-cell transcription/metabolism genes explain many MODY phenotypes.

KATP channel and INS disorders explain important neonatal presentations.

Insulin receptor defects illustrate monogenic severe insulin resistance.

MODY

β-cell function

Neonatal

Channel / insulin

Type A

Insulin receptor

Slide 72 · Selected references

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. Chapter 24; Table 24.6.

American Diabetes Association. Standards of Care in Diabetes—2026. Section 2: Diagnosis and Classification.

Naylor R, et al. Maturity-Onset Diabetes of the Young Overview. GeneReviews, NCBI Bookshelf.

Textbook framework

2026 clinical criteria

Genetic phenotype detail